Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $950.00 Price Target at JPMorgan Chase & Co.

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by investment analysts at JPMorgan Chase & Co. from $850.00 to $950.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 26.24% from the stock’s current price.

REGN has been the subject of a number of other reports. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday. BMO Capital Markets upped their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Guggenheim lifted their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday. Finally, Canaccord Genuity Group lifted their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $799.74.

Regeneron Pharmaceuticals Trading Up 1.5%

NASDAQ REGN traded up $11.10 during trading hours on Monday, reaching $752.55. The company’s stock had a trading volume of 354,676 shares, compared to its average volume of 894,991. The stock has a market cap of $79.09 billion, a P/E ratio of 18.10, a P/E/G ratio of 1.92 and a beta of 0.40. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $821.11. The firm has a fifty day simple moving average of $758.39 and a 200-day simple moving average of $651.29. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.77 and a quick ratio of 4.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the business earned $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 7.02% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently bought and sold shares of REGN. Del Sette Capital Management LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $2,253,000. Ashton Thomas Securities LLC increased its holdings in Regeneron Pharmaceuticals by 2.4% in the 4th quarter. Ashton Thomas Securities LLC now owns 1,214 shares of the biopharmaceutical company’s stock valued at $938,000 after purchasing an additional 29 shares in the last quarter. Composition Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals by 8.0% during the fourth quarter. Composition Wealth LLC now owns 3,742 shares of the biopharmaceutical company’s stock valued at $2,888,000 after acquiring an additional 276 shares in the last quarter. Kornitzer Capital Management Inc. KS bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $1,460,000. Finally, PFA Pension Forsikringsaktieselskab bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $71,861,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat consensus — EPS $11.44 vs $10.74 and revenue $3.88B vs $3.76B; management highlighted steady revenue growth. This earnings beat is the primary catalyst behind analyst revisions and the stock lift. Article Title
• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $865, signaling strong analyst conviction and adding upside to sentiment. Article Title
• Positive Sentiment: Wells Fargo and Cantor Fitzgerald raised price targets to $800 (Wells Fargo moved from $745), and Cantor set an overweight — these upgrades add demand-side support for the stock. Article Title
• Positive Sentiment: Clinical data flow: Regeneron highlighted EYLEA HD® (aflibercept 8 mg) presentations at Angiogenesis 2026, including 64‑week QUASAR and Phase 3b ELARA results — positive readthrough for the retinal franchise and future growth prospects. Article Title
• Positive Sentiment: TD Cowen and other outlets raised targets / highlighted Regeneron’s pipeline and recent decision to start paying a dividend — factors that can attract income and growth-focused investors. Article Title
• Neutral Sentiment: Morgan Stanley nudged its target from $768 to $769 and kept an “equal weight” rating — a modest, neutral adjustment that suggests limited near‑term change in conviction. Article Title
• Neutral Sentiment: Truist trimmed its target slightly (from $820 to $818) but left a “buy” rating — a small technical tweak without a major signal change. Article Title
• Neutral Sentiment: Commentary pieces note a “valuation gap” vs. pipeline progress and discuss whether REGN looks attractively priced — informative background but less likely to move price than earnings and analyst actions. Article Title

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.